Clinical trials
Completed Colitis, Ulcerative trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
817 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 3 |
| 2002 | 7 |
| 2003 | 17 |
| 2004 | 11 |
| 2005 | 17 |
| 2006 | 24 |
| 2007 | 30 |
| 2008 | 26 |
| 2009 | 26 |
| 2010 | 24 |
| 2011 | 36 |
| 2012 | 45 |
| 2013 | 38 |
| 2014 | 48 |
| 2015 | 57 |
| 2016 | 57 |
| 2017 | 48 |
| 2018 | 50 |
| 2019 | 41 |
| 2020 | 44 |
| 2021 | 45 |
| 2022 | 37 |
| 2023 | 35 |
| 2024 | 34 |
| 2025 | 9 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 817 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takeda | 33 |
| Pfizer | 22 |
| AbbVie | 20 |
| Ferring Pharmaceuticals | 16 |
| Bausch Health Americas, Inc. | 15 |
| Shire | 14 |
| Janssen Research & Development, LLC | 10 |
| Mayo Clinic | 10 |
| Second Affiliated Hospital of Wenzhou Medical University | 9 |
| Bristol-Myers Squibb | 8 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 817 |
| Crohn Disease | 294 |
| Inflammatory Bowel Diseases | 275 |
| Colitis | 26 |
| Arthritis, Rheumatoid | 22 |
| Arthritis, Psoriatic | 17 |
| Spondylitis, Ankylosing | 16 |
| Irritable Bowel Syndrome | 13 |
| Psoriasis | 12 |
| Ulcer | 12 |
Trials
Showing 1 to 25 of 817. Each trial links to its page on Pharma Observatory.
717 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.